hotspot -WSS

hotspot

author：explore 2025-10-02 23:31:40 - browse：8992

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Orchard's therapy for neuron disease in children wins FDA approval

entertainment

WSS

Maisha Meds is a PBM, but don't call it that

Leading voice in opioid treatment defends methadone clinic system

Positive childhood experiences can help future health

High breast density mammograms need follow

Medicare drug price lawsuits could be good politics for Biden

AstraZeneca to buy developer of next

knowledge

hotspot

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth increases loan offers after Change Healthcare outage

In age of alternative facts, a scholarly course on calling out crap

Asbestos, a deadly carcinogen, banned by EPA

Cancer drug shortages should be causing more outrage

Baby aspirin cuts fat buildup in liver disease patients, in small study

Moonlake's readout produced a cash windfall. Risks remain

FDA endorses new sterilization method for medical devices

BioMarin wins approval for gene therapy to treat hemophilia A

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Wikipedia

Stop the failed accountable care organization experiment

Pumping milk in bathrooms at health conferences is common

Creating egg and sperm cells from stem cells raises ethical issues

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Future doctors should be trained to promote social change

Inaction leaves children at risk from dangerous chemotherapy drug

entertainment

Wikipedia

focus

focus